Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies

NCT05006794 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05006794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05006794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
September 15, 2021
Completion date
June 16, 2025
Enrollment
37 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

solid malignancies